- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
University of Toronto
Headquarters: Toronto, ON, Canada
Website: http://www.utoronto.com
Year Founded: 1827
Status: Non-biopharma
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Oct 10, 2024
Discovery & Translation
Science Spotlight: As miRNAs get Nobel Prize, targeting advances continue
BioCentury’s roundup of translational innovation also features Vedanta’s solution to GI infection, Takeda’s exon-skipping delivery tech, and more
BioCentury | Aug 8, 2024
Discovery & Translation
Science Spotlight: Stopping herpes from entering neurons, tissue-specific nanoparticles, and more
BioCentury’s roundup of translational innovations
BioCentury | Jun 4, 2024
Deals
Biotech M&A, Biosecure expands & ASCO update: a BioCentury podcast
An M&A quartet. House China committee’s new focus. Colorectal cancer immunotherapies.
BioCentury | May 29, 2024
Deals
Clinical readout spurred Merck’s $1.3B takeout of VC-backed ophthalmic play EyeBio
In milestone-heavy deal worth up to $3B total, the pharma makes a big commitment to late-stage candidate for retinal diseases
BioCentury | Apr 24, 2024
Product Development
Next-wave radiopharmaceuticals: insights from AACR
Fusion added to view of ɑ-emitters in lutetium-experienced patients, as Novartis, RayzeBio gave peeks at programs with broad indication potential
BioCentury | Mar 23, 2024
Discovery & Translation
Science spotlight: AbbVie’s ADC for inflammation, plus HepaRegeniX’s liver failure therapy and more
BioCentury’s roundup of translational innovations
BioCentury | Apr 26, 2023
Finance
April 26 Quick Takes: Orbital’s $270M A round is year’s largest so far
Plus: Medicare to cover Leqembi, if approved; Sangamo restructuring; and updates from Roche, GSK, Seres and more
BioCentury | Mar 7, 2023
Product Development
Eyebiotech targets Wnt pathway with first retinal program
Biotech discloses details one year after $65M series A round
BioCentury | Feb 3, 2023
Discovery & Translation
Personalized CAR T cell stimulation, plus platforms from Flashpoint, AbSeek and TBG
BioCentury’s roundup of translational news
BioCentury | Jan 21, 2023
Discovery & Translation
Epigenome editing for X-linked diseases; plus a rapid platform for human mAb generation and more
BioCentury’s roundup of translational news
Items per page:
1 - 10 of 291